Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • NEWS AND VIEWS

T cells engineered to target senescence

Senescence is a hallmark of cellular ageing and contributes to many diseases. A new method enabling immune cells to target senescent cells might offer improved therapeutic options.
  1. Verena Wagner

    1. Verena Wagner is at the MRC London Institute of Medical Sciences, London W12 0NN, UK, and at the Institute of Clinical Sciences, Faculty of Medicine, Imperial College London.

    View author publications

    You can also search for this author in PubMed  Google Scholar

  2. Jesús Gil

    1. Jesús Gil is at the MRC London Institute of Medical Sciences, London W12 0NN, UK, and at the Institute of Clinical Sciences, Faculty of Medicine, Imperial College London.

    View author publications

    You can also search for this author in PubMed  Google Scholar

Senescence is a form of cellular stress response. In some circumstances it can be harmful, and efforts are under way to develop therapies that target senescent cells. Writing in Nature, Amor et al.1 describe a method that selectively removes senescent cells in mice.

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

Nature 583, 37-38 (2020)

doi: https://doi.org/10.1038/d41586-020-01759-x

References

  1. Amor, C. et al. Nature 583, 127–132 (2020).

    Article  Google Scholar 

  2. Gorgoulis, V. et al. Cell 179, 813–827 (2019).

    Article  PubMed  Google Scholar 

  3. Baker, D. J. et al. Nature 530, 184–189 (2016).

    Article  PubMed  Google Scholar 

  4. Kang, T.-W. et al. Nature 479, 547–551 (2011).

    Article  PubMed  Google Scholar 

  5. Lim, W. A. & June, C. H. Cell 168, 724–740 (2017).

    Article  PubMed  Google Scholar 

  6. Curovic, V. R. et al. Diabetes Care 42, 1112–1119 (2019).

    Article  PubMed  Google Scholar 

  7. Quaglia, M., Musetti, C. & Cantaluppi, V. N. Engl. J. Med. 374, 890–891 (2016).

    Article  PubMed  Google Scholar 

  8. Wang, L. & Bernards, R. Front. Med. 12, 490–495 (2018).

    Article  PubMed  Google Scholar 

  9. Ovadya, Y. & Krizhanovsky, V. J. Clin. Invest. 128, 1247–1254 (2018).

    Article  PubMed  Google Scholar 

  10. Brudno, J. N. & Kochenderfer, J. N. Blood 127, 3321–3330 (2016).

    Article  PubMed  Google Scholar 

  11. Eggert, T. et al. Cancer Cell 30, 533–547 (2016).

    Article  PubMed  Google Scholar 

  12. Kim, K. M. et al. Genes Dev. 31, 1529–1534 (2017).

    Article  PubMed  Google Scholar 

  13. Frescas, D. et al. Proc. Natl Acad. Sci. USA 114, E1668–E1677 (2017).

    Article  PubMed  Google Scholar 

Download references

Competing Interests

J.G. has acted as a consultant for Unity Biotechnology, Geras Bio and Merck KGaA; owns equity in Unity Biotechnology and Geras Bio and is a named inventor in an MRC patent related to senolytic therapies.

Subjects

Latest on:

Nature Careers

Jobs

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing

Search

Advanced search

Quick links